Literature DB >> 7687188

Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

L N Jørgensen1, P Wille-Jørgensen, O Hauch.   

Abstract

To evaluate the thromboprophylactic use of low molecular weight heparins (LMWHs), publications from 27 orthopaedic trials and 35 studies of patients undergoing general or gynaecological surgery were scrutinized and subjected to a partial meta-analysis. In orthopaedic surgery, LMWHs were superior to placebo or dextran and at least as efficient as unfractionated heparin in the prevention of deep vein thrombosis (DVT). Compared with unfractionated heparin, one of the LMWH preparations significantly reduced the total incidence of DVT. The rate of non-fatal pulmonary embolism was 0.49 per cent in patients receiving LMWH and 1.22 per cent in controls. Seven orthopaedic patients (0.15 per cent) died from pulmonary embolism, none of whom received LMWH. In general surgery, the LMWHs were at least as efficient as unfractionated heparin, with a trend towards a lower risk of pulmonary embolism with the former. Compared with unfractionated heparin, LMWHs did not reduce the postoperative mortality rate, nor did they cause haemorrhage. LMWHs provide safe and efficient prophylaxis by administration once daily.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687188     DOI: 10.1002/bjs.1800800607

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  26 in total

Review 1.  Extracts from "clinical evidence": hip fracture.

Authors:  W J Gillespie
Journal:  BMJ       Date:  2001-04-21

2.  Post-stent management with a pneumatic groin compression device and self injected low molecular weight heparin.

Authors:  R H Stables; U Sigwart
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 3.  The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis.

Authors:  D Bergqvist
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-08-06       Impact factor: 4.200

Review 5.  Developments in antithrombotic therapy: state of the art anno 1996.

Authors:  H ten Cate; M T Nurmohamed; J W ten Cate
Journal:  Pharm World Sci       Date:  1996-12

Review 6.  Hip fracture.

Authors:  David Oliver; Richard Griffiths; James Roche; Opinder Sahota
Journal:  BMJ Clin Evid       Date:  2010-05-28

Review 7.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

8.  Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment.

Authors:  Kevin R Rice; Stephen A Brassell; David G McLeod
Journal:  Rev Urol       Date:  2010

Review 9.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

Authors:  R Ferriols-Lisart; F Ferriols-Lisart; V Jiménez-Torres
Journal:  Pharm World Sci       Date:  2002-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.